Ascendis Pharma A/S (NASDAQ:ASND) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Shares of Ascendis Pharma A/S (NASDAQ:ASND) have received a consensus recommendation of “Moderate Buy” from the thirteen analysts that are currently covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a hold recommendation and twelve have assigned a buy recommendation to the company. The average 1 year price objective among analysts that have issued ratings on the stock in the last year is $191.77.

Several equities analysts recently commented on the company. Oppenheimer dropped their target price on Ascendis Pharma A/S from $190.00 to $180.00 and set an “outperform” rating for the company in a research note on Friday, November 15th. StockNews.com raised shares of Ascendis Pharma A/S from a “sell” rating to a “hold” rating in a research report on Wednesday, November 20th. Stifel Nicolaus boosted their price objective on Ascendis Pharma A/S from $200.00 to $207.00 and gave the company a “buy” rating in a research report on Friday, November 15th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $170.00 target price on shares of Ascendis Pharma A/S in a research report on Friday, November 15th. Finally, Citigroup lifted their target price on shares of Ascendis Pharma A/S from $178.00 to $207.00 and gave the stock a “buy” rating in a research report on Tuesday, September 17th.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. SG Americas Securities LLC purchased a new stake in Ascendis Pharma A/S in the first quarter worth $288,000. ProShare Advisors LLC grew its holdings in Ascendis Pharma A/S by 9.9% during the 1st quarter. ProShare Advisors LLC now owns 4,025 shares of the biotechnology company’s stock valued at $608,000 after buying an additional 361 shares in the last quarter. Bessemer Group Inc. grew its holdings in shares of Ascendis Pharma A/S by 61.0% in the first quarter. Bessemer Group Inc. now owns 876 shares of the biotechnology company’s stock valued at $132,000 after purchasing an additional 332 shares in the last quarter. Nan Fung Group Holdings Ltd bought a new stake in Ascendis Pharma A/S during the first quarter worth approximately $2,056,000. Finally, Capital International Investors raised its holdings in Ascendis Pharma A/S by 0.5% during the 1st quarter. Capital International Investors now owns 2,191,312 shares of the biotechnology company’s stock valued at $331,261,000 after buying an additional 10,044 shares during the period.

Ascendis Pharma A/S Stock Up 5.8 %

Shares of ASND stock opened at $129.81 on Wednesday. Ascendis Pharma A/S has a 52-week low of $90.13 and a 52-week high of $161.00. The stock’s 50-day moving average price is $133.22 and its 200 day moving average price is $132.19. The stock has a market capitalization of $7.87 billion, a PE ratio of -16.07 and a beta of 0.66.

Ascendis Pharma A/S (NASDAQ:ASND) last announced its quarterly earnings data on Tuesday, September 3rd. The biotechnology company reported ($2.05) EPS for the quarter, missing the consensus estimate of ($1.54) by ($0.51). The company had revenue of $38.75 million for the quarter, compared to analysts’ expectations of $94.74 million. Analysts expect that Ascendis Pharma A/S will post -7.45 earnings per share for the current fiscal year.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.